Abstract:Background: Prostate cancer remains the second deadliest cancer for American men despite clinical advancements. Currently, magnetic resonance imaging (MRI) is considered the most sensitive non-invasive imaging modality that enables visualization, detection, and localization of prostate cancer, and is increasingly used to guide targeted biopsies for prostate cancer diagnosis. However, its utility remains limited due to high rates of false positives and false negatives as well as low inter-reader agreements. Purpose: Machine learning methods to detect and localize cancer on prostate MRI can help standardize radiologist interpretations. However, existing machine learning methods vary not only in model architecture, but also in the ground truth labeling strategies used for model training. We compare different labeling strategies and the effects they have on the performance of different machine learning models for prostate cancer detection on MRI. Methods: Four different deep learning models (SPCNet, U-Net, branched U-Net, and DeepLabv3+) were trained to detect prostate cancer on MRI using 75 patients with radical prostatectomy, and evaluated using 40 patients with radical prostatectomy and 275 patients with targeted biopsy. Each deep learning model was trained with four different label types: pathology-confirmed radiologist labels, pathologist labels on whole-mount histopathology images, and lesion-level and pixel-level digital pathologist labels (previously validated deep learning algorithm on histopathology images to predict pixel-level Gleason patterns) on whole-mount histopathology images. The pathologist and digital pathologist labels (collectively referred to as pathology labels) were mapped onto pre-operative MRI using an automated MRI-histopathology registration platform. Results: Radiologist labels missed cancers (ROC-AUC: 0.75-0.84), had lower lesion volumes (~68% of pathology lesions), and lower Dice overlaps (0.24-0.28) when compared with pathology labels. Consequently, machine learning models trained with radiologist labels also showed inferior performance compared to models trained with pathology labels. Digital pathologist labels showed high concordance with pathologist labels of cancer (lesion ROC-AUC: 0.97-1, lesion Dice: 0.75-0.93). Machine learning models trained with digital pathologist labels had the highest lesion detection rates in the radical prostatectomy cohort (aggressive lesion ROC-AUC: 0.91-0.94), and had generalizable and comparable performance to pathologist label-trained-models in the targeted biopsy cohort (aggressive lesion ROC-AUC: 0.87-0.88), irrespective of the deep learning architecture. Moreover, machine learning models trained with pixel-level digital pathologist labels were able to selectively identify aggressive and indolent cancer components in mixed lesions on MRI, which is not possible with any human-annotated label type. Conclusions: Machine learning models for prostate MRI interpretation that are trained with digital pathologist labels showed higher or comparable performance with pathologist label-trained models in both radical prostatectomy and targeted biopsy cohort. Digital pathologist labels can reduce challenges associated with human annotations, including labor, time, inter- and intra-reader variability, and can help bridge the gap between prostate radiology and pathology by enabling the training of reliable machine learning models to detect and localize prostate cancer on MRI.

Location-based Radiology Report-Guided Semi-supervised Learning for Prostate Cancer Detection

Category-Level Regularized Unlabeled-to-Labeled Learning for Semi-supervised Prostate Segmentation with Multi-site Unlabeled Data

Multiparametric Ultrasound and Machine Learning for Prostate Cancer Localization

Machine Learning for the Prediction of Prostate Cancer Biopsy Based on 3D Dynamic Contrast-Enhanced Ultrasound Quantification

Annotation-efficient cancer detection with report-guided lesion annotation for deep learning-based prostate cancer detection in bpMRI

Uncertainty-Aware Semi-Supervised Learning for Prostate MRI Zonal Segmentation

Prostate cancer inference via weakly-supervised learning using a large collection of negative MRI

Separated collaborative learning for semi-supervised prostate segmentation with multi-site heterogeneous unlabeled MRI data

Self-Supervised Learning with Limited Labeled Data for Prostate Cancer Detection in High Frequency Ultrasound

Automatic diagnosis and grading of Prostate Cancer with weakly supervised learning on whole slide images

Weakly supervised deep learning model with size constraint for prostate cancer detection in multiparametric MRI and generalization to unseen domains

AI-assisted prostate cancer detection and localisation on biparametric MR by classifying radiologist-positives

Deep learning for fully automatic detection, segmentation, and Gleason grade estimation of prostate cancer in multiparametric magnetic resonance images

Deep Attentive Panoptic Model for Prostate Cancer Detection Using Biparametric MRI Scans

Prostate Cancer Malignancy Detection and localization from mpMRI using auto-Deep Learning: One Step Closer to Clinical Utilization

Semi-supervised learning for ABUS tumor detection using deep learning method

Fully automated detection and localization of clinically significant prostate cancer on MR images using a cascaded convolutional neural network

Boosting Medical Image-based Cancer Detection via Text-guided Supervision from Reports

Deep Learning-based Unsupervised Domain Adaptation via a Unified Model for Prostate Lesion Detection Using Multisite Biparametric MRI Datasets

Bridging the gap between prostate radiology and pathology through machine learning

Semi-Supervised and Self-Supervised Collaborative Learning for Prostate 3D MR Image Segmentation